Regulus Therapeutics Inc.
RGLSUnlisted company$26 Mlast known market cap, Jan 2024 — no current value
World rank
—
no current market cap
Revenue
—
annual
Net income
—
Employees
—
Regulus Therapeutics Inc. timeline
1 events, 2012
- 2012
- 🔔· approximateInitial public offering on Nasdaq
Events of Regulus Therapeutics Inc. from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Regulus Therapeutics Inc.
- Acquisitions and changes
- No longer listed: ticker RGLS is not in the SEC's, the US exchanges' or FINRA's lists of traded securities (checked 14 November 2026).
Market cap history
World rank over time
▼ down 2,983 places since 2020
Rank in USA: #4,462 (Jan 2020) · #3,775 (Jan 2021) · #4,982 (Jan 2022) · #5,261 (Dec 2022) · #5,064 (Jul 2023) · #4,297 (Jan 2024)
Mutual funds holding Regulus Therapeutics Inc.#
1 funds hold shares worth $0 M. Since their previous reports 0 added shares and 0 sold.
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 The Gabelli ABC FundGabelli Funds, LLC | 60,000 | $0 M | — | 0.01% | no change | Jun 30, 2026 |
As of Jun 30, 2026
Markets and events: Regulus Therapeutics Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Short interest, 2025-06-13
1.8 M
1.35 days to cover
Shares sold short, last 15 reportsAll stocks →
Trading halts
- 2025-06-24 23:50 UTC, code D, resumed 04:00 UTC
- 2025-04-30 10:55 UTC, code T3, resumed 11:30 UTC
Fails to deliver
- : 570 shares at $8.20
- : 17,945 shares at $8.22
- : 413 shares at $7.94
- : 4,464 shares at $7.93
- : 9,949 shares at $7.91
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Regulus Therapeutics Inc.🇺🇸 | $26 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
How current the figures are
- Market cap:
- Jan 5, 2024 (last known)
- Profile updated:
- Nov 14, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Regulus Therapeutics Inc.? Verify and update this profile — free
Show Regulus Therapeutics Inc.'s ranking on your website Get the badge
The badge updates itself as the ranking changes.